A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer

被引：0

作者：

Church, David N. ^{[1
]}

Price, Chris G. A. ^{[2
]}

机构：

[1] Univ Oxford, John Racliffe Hosp, Weatherall Inst Mol Med, Headley Way, Oxford OX3 9DS, England

[2] Bristol Haematol & Oncol Ctr, Bristol BS1 8ED, Avon, England

来源：

CLINICAL MEDICINE INSIGHTS-THERAPEUTICS | 2009年 / 1卷

关键词：

breast cancer; trastuzumab; metastatic; ERBB2; HER2;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The ERBB2 or HER2 receptor is overexpressed in 25% of breast cancers and is associated with poor prognosis. Trastuzumab, a monoclonal antibody targeting HER2 has been demonstrated to improve survival when combined with chemotherapy for the treatment of HER2 overexpressing metastatic breast cancer (MBC). Further studies have endeavoured to clarify the optimum chemotherapy regimen in combination with trastuzumab for MBC and its use together with novel biological agents. This review summarises these data together with preclinical studies exploring the mechanism of trastuzumab action and causes of drug resistance. The frequent incidence of brain metastases in patients on trastuzumab is highlighted, and data on the continuation of trastuzumab following CNS and non-CNS progression reviewed.

引用

页码：557 / 570

页数：14

共 50 条

[1] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
Chang, Helena R.
CANCER, 2010, 116 (12) : 2856 - 2867
[2] Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy
Montemurro, Filippo
Donadio, Michela
Clavarezza, Matteo
Redana, Stefania
Jacomuzzi, Maria Elena
Valabrega, Giorgio
Danese, Saverio
Vietti-Ramus, Guido
Durando, Antonio
Venturini, Marco
Aglietta, Massimo
ONCOLOGIST, 2006, 11 (04) : 318 - 324
[3] Late-onset cardiotoxicity in patients with HER2-positive metastatic breast cancer receiving trastuzumab-based therapy
Alowais, Shuroug A.
Luk, Samantha O.
Kim, E. Bridget
Alsuhebany, Nada
Zangardi, Mark
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (06) : 992 - 998
[4] PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
Tekesin, Kemal
Akar, Emre
Gunes, Mehmet Emin
Bayrak, Savas
Ozturk, Tulin
Altinay, Serdar
Tural, Deniz
JOURNAL OF BUON, 2019, 24 (05): : 1920 - 1926
[5] Rechallenge of Trastuzumab-based Therapy in HER2-Positive Breast Cancer Patients who Progressed Under TDM-1
Dogan, Izzet
Ahmed, Melin Aydan
Yildiz, Anil
Vatansever, Sezai
INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2024, 15 (03) : 484 - 488
[6] HER-2-positive metastatic breast cancer: Optimizing trastuzumab-based therapy
Jackisch, Christian
ONCOLOGIST, 2006, 11 : 34 - 41
[7] Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
Di Cosimo, Serena
Appierto, Valentina
Pizzamiglio, Sara
Silvestri, Marco
Baselga, Jose
Piccart, Martine
Huober, Jens
Izquierdo, Miguel
de la Pena, Lorena
Hilbers, Florentine S.
de Azambuja, Evandro
Untch, Michael
Pusztai, Lajos
Pritchard, Kathleen
Nuciforo, Paolo
Vincent-Salomon, Anne
Symmans, Fraser
Apolone, Giovanni
de Braud, Filippo G.
Iorio, Marilena, V
Verderio, Paolo
Daidone, Maria Grazia
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (04)
[8] Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy
Sohita Dhillon
Drugs, 2014, 74 : 675 - 686
[9] Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer From Early Scientific Development to Foundation of Care
Brufsky, Adam
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (02): : 186 - 195
[10] Trastuzumab beyond progression in HER2-positive metastatic breast cancer
Al-Naqqash, Manwar
Jasim Al-Serarati, Waleed
Farooq Kareem, Tara
BREAST JOURNAL, 2021, 27 (03) : 297 - 299

← 1 2 3 4 5 →